Do analysts recommend INKT or FTFT?

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 227.41%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate MENS or INKT?

MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 227.41%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, MENS or INKT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is MENS or INKT more profitable?

Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A MiNK Therapeutics N/A N/A -118.57%

Is INKT or NBP more profitable?

Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% I-Mab N/A N/A N/A

MiNK Therapeutics (INKT) Competitors

$10.69 +0.19 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$10.40 -0.29 (-2.70%)

As of 07:34 PM Eastern

Compare

INKT vs. FTFT, MENS, NBP, KROS, and RNA

Should you buy MiNK Therapeutics stock or one of its competitors? MarketBeat compares MiNK Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiNK Therapeutics include Future FinTech Group (FTFT), Jyong Biotech (MENS), I-Mab (NBP), Keros Therapeutics (KROS), and Avidity Biosciences (RNA).

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Future FinTech Group	$3.50M	0.49	-$4.62M	-$12.68	N/A

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -37.76%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Future FinTech Group	-37.76%	-13.08%	-10.33%

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 1.5% of Future FinTech Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

In the previous week, MiNK Therapeutics' average media sentiment score of 0.00 equaled Future FinTech Group'saverage media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Future FinTech Group	Neutral

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 227.41%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 14 factors compared between the two stocks.

How does MiNK Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

In the previous week, Jyong Biotech had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for MiNK Therapeutics. Jyong Biotech's average media sentiment score of 0.59 beat MiNK Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Positive
MiNK Therapeutics	Neutral

MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 227.41%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

Jyong Biotech has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
MiNK Therapeutics	N/A	N/A	-118.57%

Summary

MiNK Therapeutics beats Jyong Biotech on 6 of the 11 factors compared between the two stocks.

How does MiNK Therapeutics compare to I-Mab?

MiNK Therapeutics (NASDAQ:INKT) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

MiNK Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

In the previous week, MiNK Therapeutics' average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
I-Mab	Neutral

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
I-Mab	N/A	N/A	N/A

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MiNK Therapeutics has higher earnings, but lower revenue than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
I-Mab	$3.89M	47.87	-$46.27M	-$0.36	N/A

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 227.41%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 459.01%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

I-Mab beats MiNK Therapeutics on 7 of the 10 factors compared between the two stocks.

How does MiNK Therapeutics compare to Keros Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

MiNK Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 227.41%. Keros Therapeutics has a consensus target price of $20.40, suggesting a potential upside of 101.78%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe MiNK Therapeutics is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Keros Therapeutics had 8 more articles in the media than MiNK Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 beat Keros Therapeutics' score of -0.31 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Keros Therapeutics	Neutral

MiNK Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. MiNK Therapeutics' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Keros Therapeutics has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Keros Therapeutics	$244.06M	0.82	$87.01M	-$3.01	N/A

Summary

MiNK Therapeutics and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Avidity Biosciences?

MiNK Therapeutics (NASDAQ:INKT) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

MiNK Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MiNK Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Avidity Biosciences	$36.68M	5.28	-$322.30M	-$0.97	N/A

In the previous week, Avidity Biosciences had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for MiNK Therapeutics. Avidity Biosciences' average media sentiment score of 1.02 beat MiNK Therapeutics' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Avidity Biosciences	Positive

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 227.41%. Avidity Biosciences has a consensus target price of $67.60, suggesting a potential upside of 496.65%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28

MiNK Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. MiNK Therapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Summary

Avidity Biosciences beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$52.31M	$3.55B	$6.86B	$12.45B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.76	4.33	223.77	22.69
Price / Sales	N/A	1,264.13	588.10	92.16
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-3.53	16.89	11.02	6.21
Net Income	-$12.49M	-$12.54M	$3.48B	$347.49M
7 Day Performance	0.94%	-0.63%	0.56%	0.89%
1 Month Performance	-8.40%	-7.41%	-4.14%	-3.60%
1 Year Performance	-27.38%	49.17%	63.23%	20.46%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.5146 of 5 stars	$10.69 +1.8%	$35.00 +227.4%	-28.7%	$52.31M	N/A	N/A	30
FTFT Future FinTech Group	0.3028 of 5 stars	$1.18 -6.3%	N/A	-96.8%	$2.35M	$3.83M	N/A	70	Positive News
MENS Jyong Biotech	N/A	$2.36 -12.9%	N/A	-88.8%	$206.04M	N/A	N/A	31	Gap Up
NBP I-Mab	1.6802 of 5 stars	$1.77 flat	$9.00 +408.5%	N/A	$204.70M	N/A	N/A	380
KROS Keros Therapeutics	2.3999 of 5 stars	$10.06 -0.8%	$20.40 +102.8%	-29.7%	$200.69M	$33.18M	N/A	100	News Coverage Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, MENS, NBP, KROS, and RNA

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Jyong Biotech?

Summary

How does MiNK Therapeutics compare to I-Mab?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Summary

How does MiNK Therapeutics compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, MENS, NBP, KROS, and RNA

How does MiNK Therapeutics compare to Future FinTech Group?

Which has better valuation and earnings, INKT or FTFT?

Is INKT or FTFT more profitable?

Do institutionals and insiders hold more shares of INKT or FTFT?

Which has more volatility & risk, INKT or FTFT?

Does the media favor INKT or FTFT?

Do analysts recommend INKT or FTFT?

Summary

How does MiNK Therapeutics compare to Jyong Biotech?

Does the media prefer MENS or INKT?

Do analysts rate MENS or INKT?

Which has stronger earnings and valuation, MENS or INKT?

Which has more risk and volatility, MENS or INKT?

Do insiders and institutionals have more ownership in MENS or INKT?

Is MENS or INKT more profitable?

Summary

How does MiNK Therapeutics compare to I-Mab?

Which has more risk and volatility, INKT or NBP?

Does the media favor INKT or NBP?

Is INKT or NBP more profitable?

Do institutionals & insiders hold more shares of INKT or NBP?

Which has preferable earnings & valuation, INKT or NBP?

Do analysts recommend INKT or NBP?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Which has more volatility and risk, INKT or KROS?

Do insiders and institutionals have more ownership in INKT or KROS?

Do analysts rate INKT or KROS?

Does the media favor INKT or KROS?

Is INKT or KROS more profitable?

Which has stronger earnings & valuation, INKT or KROS?

Summary

How does MiNK Therapeutics compare to Avidity Biosciences?

Which has more volatility and risk, INKT or RNA?

Do institutionals and insiders have more ownership in INKT or RNA?

Which has stronger valuation and earnings, INKT or RNA?

Does the media favor INKT or RNA?

Do analysts prefer INKT or RNA?

Is INKT or RNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools